Evidence map›Paper›PMID 32019905›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2020

Necrostatin-1 Alleviates Bleomycin-Induced Pulmonary Fibrosis and Extracellular Matrix Expression in Interstitial Pulmonary Fibrosis.

Fanghong Mou, Canglang Mou

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Beyond classical collagen: basement membrane collagen IV in age-associated lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  2. [Research Progress of Anti-lung Cancer Drug-related Interstitial Lung Disease].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  3. Necrostatin-1: a promising compound for neurological disorders.Frontiers in cellular neuroscience · 2024
    Review
  4. PANoptosis: Mechanism and Role in Pulmonary Diseases.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Prevention of Bleomycin-Induced Pulmonary Inflammation and Fibrosis in Mice by Bilobalide.Evidence-based complementary and alternative medicine : eCAM · 2023
    Article
  7. Necroptosis in CNS diseases: Focus on astrocytes.Frontiers in aging neuroscience · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Fanghong MouDepartment of Respiration, The People's Hospital of Kaizhou District, Chongqing, China (mainland).
Canglang MouDepartment of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
People's Hospital of Kaizhou District · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Interstitial pulmonary fibrosis (IPF) is harmful for patients' life and health. The effective treatment of IPF is lacking because of unclear pathogenesis. Necrostatin-1 has protective effects on lung injury and can suppress the fibrosis development. I this study we investigated whether necrostatin-1 could decrease the proliferation of pulmonary fibroblasts, pulmonary fibrosis and expression of extracellular matrix (ECM) in IPF. MATERIAL AND METHODS The IPF mice model was conducted by intra-tracheal injection of bleomycin (BLM) (2 mg/kg) for C57BL/6N mice. Necrostatin-1 treatment was performed with 1 mg/kg necrostatin-1 by an intravenous injection for C57BL/6N mice. Lung tissue structures and collagen deposition were observed by hematoxylin and eosin staining and Masson staining. IPF in vitro model was constructed by MRC-5 cells induced by transforming growth factor beta 1 (TGF-ß1). And, 20 μM necrostatin-1 was used to treat the TGF-ß1 induced MRC-5 cells. Cell Counting Kit-8 (CCK-8) assay detected the viability of MRC-5 cells. The expression of receptor-interacting protein kinase-1 and -3 (RIPK1 and RIPK3), alpha smooth muscle actin (alpha-SMA), collagen IV, collagen I, fibronectin (FN), and transforming growth factor-ß (TGF-ß) in lung tissues and MRC-5 cells was measured by western blot analysis. The alpha-SMA expression in lung tissues was also analyzed by immunohistochemistry. RESULTS The expression of RIPK1 and RIPK3 in lung tissues of BLM induced mice was increased. The degree of pulmonary fibrosis and expression of alpha-SMA, collagen IV, collagen I, FN, and TGF-ß in lung tissues of BLM induced mice was enhanced. The proliferation of MRC-5 cells was increased when MRC-5 cells were induced by TGF-ß. The expression of RIPK1, RIPK3, alpha-SMA, collagen IV, collagen I, and FN was increased in TGF-ß induced MRC-5 cells. And, necrostatin-1 could effectively reverse the changes of pulmonary fibrosis, RIPK1, RIPK3, and ECM in vivo and in vitro experiments. CONCLUSIONS Necrostatin-1 attenuated pulmonary fibrosis in lung tissues of BLM induced mice and inhibited the fibroblast proliferation. And, necrostatin-1 also decreased the expression of RIPK1, RIPK3, and ECM in lung tissues of BLM induced mice and TGF-ß induced fibroblasts. Necrostatin-1 could be a new effective drug for the treatment of IPF.

Indexed as

AnimalsBleomycinCell LineCell ProliferationCollagenExtracellular MatrixFibroblastsImidazolesIndolesLungLung Diseases, InterstitialMaleMice, Inbred C57BLPulmonary FibrosisReceptor-Interacting Protein Serine-Threonine KinasesTransforming Growth Factor beta1BleomycinCollagenImidazolesIndolesnecrostatin-1Receptor-Interacting Protein Serine-Threonine KinasesRipk1 protein, mouseRipk3 protein, mouseTransforming Growth Factor beta1

Identifiers

PMID32019905
PMCPMC7020761
OpenAlexW3002633502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.